HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem-cell support: A case report.

AbstractINTRODUCTION:
The efficacy of high-dose chemotherapy plus transplantation of autologous hematopoetic stem cells in patients with endometrial stromal sarcomas is unknown.
CASE REPORT:
A 39-year-old woman with Stage III endometrial stromal sarcoma (ESS) underwent radical surgery, followed by five courses of ifosfamide, adriamycin and dacarbazine postoperatively. Six months after primary surgery stem cell priming was performed. Five months later bone marrow was aspirated and high-dose chemotherapy with carboplatin, vepeside and holoxan were administered after which bone marrow was retransfused. Seven years after primary surgery the patient developed an abdominal recurrence which was removed surgically and adjuvant radiotherapy was administered. One year later the patient underwent hemicolectomy because of a new recurrence infiltrating the ascending colon. Treatment with 25 mg exemestane was begun. The patient is currently alive and free of disease nine years after the initial diagnosis.
CONCLUSION:
Aggressive chemotherapy with autologous stem-cell support seems to be ineffective in patients with ESS.
AuthorsP Klaritsch, O Reich, S Regauer, T Bauernhofer
JournalEuropean journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 27 Issue 3 Pg. 297-8 ( 2006) ISSN: 0392-2936 [Print] Singapore
PMID16800264 (Publication Type: Case Reports, Journal Article)
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Combined Modality Therapy
  • Endometrial Neoplasms (pathology, surgery, therapy)
  • Female
  • Humans
  • Sarcoma, Endometrial Stromal (secondary, surgery, therapy)
  • Stem Cell Transplantation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: